Pharmaceutical

UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis.

Apr 30, 2025 - 06:00
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis.
Read the original article

Tags:

Previous Article

Small biotechs shoulder the burdens of an uncertain biopharma sector

Next Article

Biohaven secures $600m financing as it awaits FDA prodrug decision

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pfizer says most tornado damage at key plant hit warehouse, but finished drugs also impacted

STAT+: Pfizer says most tornado damage at key plant hit...

Jul 22, 2023

Novartis’ urticaria drug meets all endpoints in Phase III trials

Novartis’ urticaria drug meets all endpoints in Phase I...

Nov 12, 2023

FDA grants fast track status to FELIQS’s FLQ-101 to prevent ROP

FDA grants fast track status to FELIQS’s FLQ-101 to pre...

Nov 5, 2024